Teva Pharmaceutical Industries (NYSE:TEVA) was upgraded by stock analysts at Credit Suisse Group from an “underperform” rating to a “neutral” rating in a note issued to investors on Friday. The brokerage presently has a $20.00 target price on the stock, up from their prior target price of $8.00. Credit Suisse Group’s price target points to a potential upside of 7.47% from the company’s current price.

A number of other equities analysts have also recently issued reports on TEVA. Guggenheim began coverage on shares of Teva Pharmaceutical Industries in a report on Tuesday, December 12th. They issued a “neutral” rating and a $16.00 target price on the stock. Piper Jaffray Companies set a $16.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Thursday. BTIG Research raised their target price on shares of Teva Pharmaceutical Industries to $20.00 in a report on Friday. Cantor Fitzgerald set a $10.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Thursday. Finally, Oppenheimer reissued a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Thursday. Five research analysts have rated the stock with a sell rating, nineteen have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Teva Pharmaceutical Industries currently has an average rating of “Hold” and a consensus price target of $20.65.

Teva Pharmaceutical Industries (NYSE TEVA) opened at $18.61 on Friday. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries has a twelve month low of $10.85 and a twelve month high of $38.31. The stock has a market cap of $17,576.80, a PE ratio of 4.00 and a beta of 0.55.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Capital Research Global Investors increased its stake in shares of Teva Pharmaceutical Industries by 13.8% during the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock valued at $2,535,518,000 after acquiring an additional 9,260,426 shares during the period. Franklin Resources Inc. increased its stake in shares of Teva Pharmaceutical Industries by 11.1% during the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock valued at $2,218,958,000 after acquiring an additional 6,685,844 shares during the period. FMR LLC increased its stake in shares of Teva Pharmaceutical Industries by 16.7% during the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock valued at $1,423,310,000 after acquiring an additional 6,115,853 shares during the period. Macquarie Group Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 350.3% during the third quarter. Macquarie Group Ltd. now owns 4,408,331 shares of the company’s stock valued at $77,587,000 after acquiring an additional 3,429,448 shares during the period. Finally, Capital World Investors increased its stake in shares of Teva Pharmaceutical Industries by 41.9% during the second quarter. Capital World Investors now owns 11,068,200 shares of the company’s stock valued at $367,686,000 after acquiring an additional 3,268,200 shares during the period. 52.05% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries (TEVA) Rating Increased to Neutral at Credit Suisse Group” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/teva-pharmaceutical-industries-teva-rating-increased-to-neutral-at-credit-suisse-group/1769009.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.